logo
  

Engie 9-month EBIT, Revenue Climb; Lifts FY22 Outlook - Quick Facts

Engie SA (ENGQF.PK,ENGIY.PK), a French energy provider, reported Thursday that nine-month earnings before interest and tax or EBIT climbed 84.4 percent to 7.3 billion euros from last year's 3.9 billion euros.

EBITDA was 10.7 billion euros, up 47.7 percent from 7.2 billion euros a year ago. EBITDA grew 44.9 percent on an organic basis.

Revenue climbed 85.3 percent to 69.3 billion euros from 37.4 billion euros last year. Revenue went up 82.9 percent on an organic basis.

Looking ahead, the company upgraded its fiscal 2022 forecast.

Net recurring income Group share or NRIgs for the year is now expected to be in the range of 4.9 billion euros to 5.5 billion euros, based on indicative EBITDA range of 13.2 billion euros to 14.2 billion euros and EBIT range of 8.5 billion euros to 9.5 billion euros.

Previously, the company expected NRIgs in the range of 3.8 billion euros to 4.4 billion euros, based on indicative EBITDA range of 11.7 billion euros to 12.7 billion euros and EBIT range of 7.0 billion euros to 8.0 billion euros.

Further, the company reaffirmed its dividend policy, with a 65 percent to 75 percent payout ratio based on NRIgs, and a floor of 0.65 euro per share for the 2021 to 2023 period.

For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Elon Musk's brain implant firm Neuralink said it has received approval from the U.S. Food and Drug Administration to conduct first-in-human clinical trials. In a tweet, Neuralink said, "We are excited to share that we have received the FDA's approval to launch our first-in-human clinical study! T.W. Garner Food Co. is recalling 50,688 bottles of 12 oz. Texas Pete Buffalo Wing Sauce citing undeclared soy, the U.S. Food and Drug Administration said. The agency noted that some of the bottles may contain Texas Pete Extra Mild Wing Sauce which contains soy. The recall involves Texas Pete Buffalo Wing Sauce with best used by 120623T 065239 UPC 0 75500 10011 6. The U.S. Food and Drug Administration approved Pfizer Inc's COVID-19 oral antiviral pill Paxlovid for the treatment of mild-to-moderate COVID-19 in adults. Paxlovid is the first oral treatment, and the fourth drug, approved by the agency to treat COVID-19 in adults. Paxlovid (nirmatrelvir tablets and ritonavir tablets, co-packaged for oral use) has been approved to treat adults who are at high...
RELATED NEWS
Follow RTT